CHINARES PHARMA announced that its Type 2 diabetes drug has received a notice of approval for a supplemental drug application

AASTOCKS
2025.12.02 05:13

CHINARES PHARMA (03320.HK) announced that its subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for Pioglitazone Hydrochloride Dispersible Tablets, which is regarded as passing the consistency evaluation.

Pioglitazone Hydrochloride Dispersible Tablets are used for the treatment of type 2 diabetes

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer